#Glenmark Life Sciences

[pharmawalksjobs]

Glenmark Pharma walk-in interview for ITI, Diploma, BA, B Com, BSc, MSc, B Pham, M Pharm on 24th Oct 2024

Glenmark Life Sciences (GLS) is a prominent producer and developer of specific, high-worth, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic fields. Throughout time, we have forged robust partnerships with major generic pharmaceutical companies worldwide, enabling us to broaden our range of products and extend our global presence. Our collaborations span across 16…

[demiumresearch]

Shares of companies like Glenmark Life Sciences, Hindustan Unilever, and Lux Industries defied the bearish market sentiment as the Indian headline indices Nifty and Sensex tanked over 3% on Monday, falling by over 800 and nearly 2,600 points, respectively, after following the global cues. Glenmark Life Sciences Ltd. soared 6.76% to Rs 939.3 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group.  500 stocks on the BSE that hit their respective lower circuit limits in Monday's trade.Defied the Bearish Market Sentiment! #indianequity #bse #stockmarket # https://youtube.com/shorts/5G5Bpd8kVMA?feature=share

[walkwatertalentadvisors]

India’s API Industry Manufacturing Leadership Talent 2024

API Industry in India

The Active Pharmaceutical Ingredient (or API) industry is a crucial segment of the Indian pharma industry (which is anticipated to reach USD 65 billion by 2024) and contributes to around 35 per cent of the pharma market. India is the 3rd largest producer of APIs accounting for an 8 per cent share of the Global API Industry. 500+ different APIs are manufactured in India, and it contributes 57 per cent of APIs to the prequalified list of the WHO.

The growing antagonism between the West and China has also pushed the global pharma majors to source more from countries other than China. India’s emergence as the alternate source of bulk drugs has been quite remarkable.

To capitalize on its API potential, India is building a holistic and conducive ecosystem. In 2020, the government approved INR 6,940 crore for a production-linked incentive (PLI) scheme for the promotion of domestic manufacturing of Key Starting Materials (KSMs) / Drug Intermediaries (DIs), and APIs.

Over the next several years, the Indian API market is anticipated to increase at a CAGR of 13.7 per cent. The Indian API space has become lucrative for several investors and venture capitalists. India’s robust domestic market, advanced chemical industry, skilled workforce, stringent quality and manufacturing standards, and low costs (about 40 per cent less than that in the West) for setting up and operating a modern plant give an added advantage.

Consolidation in the API Industry

Strategic M&A and PE / VC investments driving consolidation in the API industry

As per a report by EY, PE/VC investments in India’s Pharma and life sciences industry have demonstrated an impressive CAGR of 24% over the last 5 years. Since 2022, the Indian Pharma and Healthcare sector has witnessed cumulative M&A deal value of USD 15 billion.

Interestingly, a big chunk of these investments have moved to the API sector where Private Equity players / asset management firms have pursued the strategy of driving consolidation through M&As, strategic investments in API companies and building API platforms. The industry has seen emergence of several large PE owned API platform companies.

Some of these platform companies include Advent International led Cohance Lifesciences / Suven Pharma, PAG & CX Partners led Sekhmet Pharmaventures, and Carlyle backed Viyash Lifesciences and Sequent Scientific (Animal API manufacturer).  In addition to the PE action, the sector continues to see consolidation and divestment, the recent example being the acquisition of Glenmark Lifesciences by Nirma Industries.

Scope of the Study

The API industry continues to see robust action in the Leadership hiring space. Particularly in the Manufacturing function, while demand for senior leadership talent continues to grow, their availability is increasingly becoming less. Adding to this demand supply gap, we have also seen challenges related to increased compensation levels and age profile of senior leadership talent.

This report was put together by WalkWater Talent Advisors after an exhaustive study of manufacturing leadership talent in the API industry. The reports seeks to understand some of the key trends and talent insights which are driving leadership hiring in this function.

Research Methodology

Definitions

Site Heads – Manufacturing leaders who are responsible for all operations in a manufacturing Site.

Cluster Heads – Manufacturing leaders who are responsible for driving manufacturing operations across a cluster of API Sites / Plants.

Chief Operating Officers (COO)– Leaders who are responsible for driving overall manufacturing operations across all manufacturing sites in an organization. They are reported into by Clusters Heads / multiple plant heads.

API – API (Active Pharmaceutical Ingredient) is the biologically active component of a drug that causes an intended medical effect.

Captive Organizations – Firms that manufacturing APIs for their in-house production needs

Merchant Organizations – Firms that manufacture APIs to be sold to third party customers

Key findings

Inferences: One of the startling findings of our study is that there is no diversity talent across leadership levels in the manufacturing function across all company’s studied in this report. In an era of Diversity, Equity and Inclusion, this finding is a call out to all key decision makers / influencers  of this industry to urgently address this issue so that there can be better representation of diversity and a more inclusive approach to talent growth in this industry.

Inferences: Given the highly technical nature of the manufacturing roles, it is no surprise that 95% of the leadership talent pool are Chemical engineers / Chemistry Graduates by education. More over, 41% of this talent pool are full time Masters / Doctorates.

Inferences: There are 3 emerging geographic talent clusters for API manufacturing leadership talent in India – AP + Telangana is by far the largest cluster, followed by Maharashtra and Gujarat. These 3 clusters make up more than 82% of the available leadership talent in the manufacturing function and one can expect that these 3 clusters will continue to attract a major portion of planned investments in this sector.

Inferences: A 40% churn in the leadership talent is significant in any industry and given the action happening in this industry, we expect this trend to continue to grow for the next few years. More importantly, as the industry sees continued investments leading to the manufacturing networks becoming more complex, the industry has beefed up hiring of COO candidates to provide leadership and strategic direction to manage the growth of the manufacturing operations.

Inferences: The findings suggest manufacturing leadership talent is ageing in this industry. Further as the demand supply gap widens, the industry will need to focus on better talent management strategies so that younger talent can be groomed to take up leadership responsibilities faster and more effectively. To make up the shortage of leadership talent in the near term, companies are giving extensions to existing talent beyond their retirement age. 

Inferences: Given the increased demand of leadership talent in the manufacturing function, compensation levels have increased in this industry and surprisingly the median CTC across levels are today comparable to CTC trends in FMCG industry for similar talent.

Cost to company (CTC) here means annual fixed + variable compensation. For critical talent, most companies also offer wealth creation opportunity through long term incentives / esops / stocks – this component is not part of the CTC figures above.

About Lead Authors

Rahul Shah Co-Founder & Director

Rahul brings 25+ years of industry experience, out of which, he has spent more than 22 years in the Executive Search industry. Post MBA, he worked for close to 3 years with Usha Martin’s Alloy & Steels business and then moved to the Executive Search industry with ABC Consultants. He spent more than 9 years with ABC Consultants and in his last role, he was an Executive Director responsible for running the Bangalore office, the 3rd largest office by revenues. As Co-Founder of WalkWater, he personally leads Senior Searches across sectors, with a sectoral specialization in the Consumer, Pharma and Industrial sectors. He is an Instrumentation Engineer from Bangalore University and has completed his MBA from XIM, Bhubaneswar. He is certified in Personal Profile Analysis from Thomas International. Outside work, he is a biker and loves to travel and watch movies.

Prakash HS Senior Vice President | Pharma & Lifesciences

Prakash brings 22+ years of work experience of which 6 years has been in Marketing and Sales in the Pharma industry and the last 16 years in the Executive Search industry with focus on leadership and niche hiring for the Pharma, Healthcare & Lifesciences segments. He started his career in Pharma sales, subsequently joined Pfizer and had a successful stint there. Post Pfizer, he shifted to the Executive Search industry with stints in market leading companies like ABC Consultants and Korn Ferry. At WalkWater, Prakash is the sector specialist for the Pharma, Healthcare and Life science industries and has advised several MNCs and large Indian Pharma companies on critical searches and talent advisory engagements.

[freddiemark]

Nirma Share Price: An In-depth Analysis of Investment Opportunity

Introduction to Nirma Share Price 

Investing in the stock market can be a lucrative opportunity for those seeking to grow their wealth. One such company that has caught the attention of investors is Nirma Ltd. With its impressive track record and potential for growth, Nirma Share Price has become a hot topic in the financial world. In this article, we will delve into the various aspects of Nirma Ltd, including its share price, recent developments, and investment potential.

Understanding Nirma Ltd

Nirma Ltd, a renowned company in the Indian market, has established itself as a leader in various sectors. The company's diverse portfolio includes consumer goods, chemicals, and pharmaceuticals. Nirma Ltd has a strong presence in the market and has gained the trust of investors over the years.

Nirma Share Price Movement

The Share Price Of Nirma Ltd is a crucial factor for investors to consider when making investment decisions. The price of a company's shares can indicate its financial health, market perception, and growth potential. Tracking the movement of Nirma Share Price can provide valuable insights into the company's performance and future prospects.

Recent Developments

In recent news, Nirma Ltd announced the divestment of a 75% stake in its subsidiary, 'Glenmark Life Sciences.' This strategic move has attracted attention from investors and has had an impact on Nirma Share Price. The company signed an agreement with Nirma Limited for the share sale, which has resulted in a significant milestone for both companies.

According to the regulatory filing by Glenmark Pharma, the sale of 91,895,379 shares of Glenmark Life Sciences Ltd to Nirma Ltd was finalized at a price of Rs 615 per share, aggregating to Rs 5,651.5 crore. This transaction will shape an independent growth trajectory for Glenmark Life Sciences and provide an opportunity for Nirma Ltd to strengthen shareholder value through deleveraging and enhancing its overall return profile.

Nirma Share Price Movement Analysis

The share price of Nirma Ltd has witnessed both highs and lows in recent times. On Thursday, September 21, the share price reached a 52-week high of Rs 880, creating a buzz among investors. However, on Friday, the share price dipped by 6.3% to touch a low of Rs 775. Such fluctuations in Nirma Share Price can be attributed to various factors, including market conditions, company announcements, and investor sentiment.

Analyzing Nirma Ltd's Financial Track Record

When considering an investment in a company, it is crucial to analyze its financial track record. This analysis provides insights into the company's performance over a specific period, enabling investors to make informed decisions. Let's take a closer look at Nirma Ltd's financial track record and key financial parameters.

Value Creation Analysis

Nirma Ltd's value creation index, calculated based on the company's return on capital employed (ROCE), shows the company's ability to generate value for its shareholders. Over the past ten years, Nirma Ltd has maintained a steady ROCE, ranging from 6% to 14.9%. However, the value creation index has seen fluctuations, indicating the company's performance relative to its peers.

Growth Parameters

Sales growth and earnings per share (EPS) growth are vital indicators of a company's financial health. Nirma Ltd has witnessed mixed performance in terms of sales growth over the years. While the company has experienced positive growth in some periods, there have been declines as well. EPS growth has shown a similar pattern, reflecting the company's ability to generate profits for its shareholders.

Key Financial Parameters

Examining key financial parameters such as return on equity (ROE), operating profit margin, and net profit margin helps investors gauge a company's profitability and efficiency. Nirma Ltd has maintained a decent ROE, ranging from 6% to 12.9% over the years. Operating profit margin and net profit margin have also remained stable, indicating the company's ability to generate profits.

Nirma Ltd's Management and Future Prospects

A company's management is a critical factor that can influence its performance and future prospects. Nirma Ltd boasts a strong and experienced management team, led by Chairman and Managing Director Glenn Saldanha. The company's strategic intent is to become an innovative and brand-led organization, focusing on core therapeutic areas such as dermatology, respiratory, and oncology.

The recent divestment of Glenmark Life Sciences reflects Nirma Ltd's commitment to shaping its independent growth trajectory. This move aligns with the company's strategic intent and presents an opportunity for Nirma Ltd to strengthen its position in the market and enhance shareholder value.

Conclusion

Investing in Nirma Ltd can be an attractive opportunity for investors seeking long-term growth. By analyzing Nirma Share Price, financial track record, and future prospects, investors can make informed decisions about their investments. However, it is crucial to remember that stock prices are subject to market risks, and thorough research and analysis are necessary before making any investment decisions.

Disclaimer: This article is for informational purposes only and should not be considered as investment advice. The content provided herein does not take into account individual investment objectives, financial situations, or needs. Before making any investment decisions, it is recommended to seek independent professional advice.

[moneywellglobal]

Stocks to Watch: Infosys, HUL, L&T, IndusInd Bank, M&M, IndiaMart

[sidnazpro2020]

Latest News Today - Glenmark Life Sciences IPO Subscribed Nearly 45 Times On

Latest News Today – Glenmark Life Sciences IPO Subscribed Nearly 45 Times On

Glenmark Life Sciences sold shares in the price band of ₹ 695-720 per equity share. Glenmark Life Sciences’ share sale via initial public offering (IPO) was subscribed by 44.17 times on Thursday, July 29 – the third and final day of its issue. The company’s Rs 1,513 crore IPO consisted of a fresh issue of Rs 1,060 crore and an offer for sale of Rs 453.60 crore by its promoters. The public offer…

[thinkwithlogic]

Glenmark Life Sciences IPO fully subscribed on Day 1 but grey market premium slips

Glenmark Life Sciences IPO fully subscribed on Day 1 but grey market premium slips

Glenmark Life Sciences initial public offering (IPO) opened today and received a strong response from investors, fully subscribing to the issue in less than two hours. Glenmark Life Sciences initial public offering (IPO) opened today and received a strong response from investors, fully subscribing to the issue in less than two hours. Retail investors lead the charge oversubscribing the issue.…

[tradersideology]

Glenmark Life Sciences IPO | Should you apply for Glenmark Life sciences IPO?

Glenmark Life Sciences IPO | Should you apply for Glenmark Life sciences IPO?

Another week and another IPO now this time it is an API manufacturing company and the company name is Glenmark life Sciences. We will review this IPO and decide if it is worth applying for the IPO or not. If you are following my IPO reviews I reviewed Zomato and is listed at a bumper valuation. In this article we’ll cover the Glenmark life Sciences IPO by understanding more about the company and…

[pharmawalksjobs]

Glenmark Pharmaceuticals walk-in interview for Production, Engineering on 14th July 2024

Glenmark Life Sciences Limited (GLS) is a prominent producer and developer of specific, high-worth, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic fields. Throughout time, we have forged robust partnerships with major generic pharmaceutical companies worldwide, enabling us to broaden our range of products and extend our global presence. Our collaborations span…

[transfin1]

Glenmark Life Sciences IPO - Why It May Not Be the Best Buy

The IPO of API manufacturer Glenmark Life Sciences is scheduled to hit the markets on July 27th, marking this year’s 29th public offering.

The company was spun off as a wholly-owned API business subsidiary of Glenmark Pharmaceuticals in 2018.

Even though it has been doing some good business owing to rising market and policy winds favouring generics and patent liberation, this IPO may not have come at a particularly good time, in light of Glenmark Life’s financial obligation to its parent.

Read more on why this IPO may or may not be a good buy by clicking on the link below.

https://transfin.in/glenmark-life-sciences-ipo-why-it-may-not-be-the-best-buy

[wealthfundas]

Read a full detailed article on Glenmark Life Science IPO with all information before Investing.

[sakthieswaran1997]

Initial Public Offering (IPO)

The process of issuing shares of a private firm to the public in a fresh stock issuance is known as an initial public offering (IPO). A firm can raise funds from the general public by issuing public shares. Because it often involves share premiums for current private investors, the transition from a private to a public firm can be an essential opportunity for private investors to completely realize rewards from their investment. Meanwhile, public investors are allowed to participate in the offering.



[hummingzone]

Glenmark Life Sciences share makes a tepid debut, lists 4% higher to issue price

Glenmark Life Sciences share makes a tepid debut, lists 4% higher to issue price

Glenmark Life Sciences share made a tepid debut today, rising 4.30% to Rs 751 on BSE against issue price of  Rs 720. The stock touched a high and a low of  Rs 800 and  Rs 737, respectively. Total 9.26 lakh shares changed hands amounting to turnover of Rs 71.61 crore. Market cap of the firm rose to Rs 9,441 crore. On  NSE, the pharma share listed at Rs 750 against issue price of Rs 720. Total 1.49…

[sidnazpro2020]

Latest News Today - Glenmark Life Sciences IPO Subscribed Nearly 6 Times On

Latest News Today – Glenmark Life Sciences IPO Subscribed Nearly 6 Times On

Glenmark Life Sciences is selling shares in the price band of Rs 695-720 per equity share. Glenmark Life Sciences’ share sale via initial public offering (IPO) was oversubscribed by 5.78 times on Wednesday, July 28 – the second day of its issue. The public offer opened for subscription on July 27 and will close tomorrow – July 29, remaining open for investors for a period of three days. On the…

[thinkwithlogic]

Glenmark Life Sciences Limited IPO-Details, Lot Size, Price Band, Date, GMP & Review

Glenmark Life Sciences Limited IPO-Details, Lot Size, Price Band, Date, GMP & Review

Brief History of Company Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further…

[bengalbytes]

Glenmark IPO Allotment Date, Status: Glenmark Life Sciences IPO GMP weak; Check listing date

Glenmark IPO Allotment Date, Status: Glenmark Life Sciences IPO GMP weak; Check listing date

Image Source : GLENMARKLIFESCIENCES.COM Glenmark Life Sciences IPO GMP weak; listing on Aug 6 Glenmark Life Sciences IPO allotment will be declared on Tuesday. Glenmark IPO allotment status will be available on KFintech website. KFin Technologies Private Limited is the official registrar of Glenmark Life Sciences IPO. Investors can also check Glenmark Life Sciences IPO allotment status on the…